Compare Ascendis Pharma A/S (ASND) vs Bank of America Corp (BAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Bank of America Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Bank of America Corp trades at $59.82 (market cap $423.45B). The key difference: Bank of America Corp is far larger — about 23.9× Ascendis Pharma A/S's market cap, and Bank of America Corp pays a 1.88% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BAC | |
|---|---|---|
Market Cap | $17.74B | $423.45B |
Sector | Health | Financials |
52-Week High | $277.18 | $59.90 |
52-Week Low | $163.32 | $44.92 |
Enterprise Value | $18.11B | — |
Volume | — | 55,637,172 |
Dividend Yield | — | 1.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Bank of America (BAC) trades at $59.67, up 0.71% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats and revenue growth to $113.1B in 2025 highlight fundamental strength. The stock is supported by a $2T+ deposit base and positive sentiment from media coverage of its strategic initiatives, including partnerships and hiring.
Outlook remains positive with a $63.79 consensus price target, though risks include volatile cash flows and regulatory scrutiny. Investment appeal lies in earnings momentum and potential capital returns post-stress tests, balanced by macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →
